Letter to the Editor April 15, 1997

Reply to Letter to the Editor "Pharmacologic Properties of Venlafaxine"

Robert L. Findling; Michael A. Schwartz; Daniel J. Flannery; Michael J. Manos

J Clin Psychiatry 1997;58(4):178-179

Article Abstract

Letter to the Editor

Sir: We appreciate the interest Dr. Smith has taken in our work which examined venlafaxine in adults with attention- deficit/hyperactivity disorder (ADHD). However, our rationale for initiating a clinical trial with venlafaxine in adults with this syndrome was not simply due to the fact that venlafaxine is an antidepressant. The reason we initiated a trial with venlafaxine was that the effect of venlafaxine on both serotonergic and noradrenergic neural transmission is a pharmacologic profile shared with the tricyclic antidepressants.

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.